Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
about
Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitorsCharting a Path to Success in Virtual ScreeningNew insights into the in silico prediction of HIV protease resistance to nelfinavirStructural Evidence for Effectiveness of Darunavir and Two Related Antiviral Inhibitors against HIV-2 ProteaseStructure of HIV-1 protease in complex with potent inhibitor KNI-272 determined by high-resolution X-ray and neutron crystallographyDesign of HIV-1 Protease Inhibitors with Pyrrolidinones and Oxazolidinones as Novel P1′-Ligands To Enhance Backbone-Binding Interactions with Protease: Synthesis, Biological Evaluation, and Protein−Ligand X-ray Studies ∞Design, Synthesis, Protein−Ligand X-ray Structure, and Biological Evaluation of a Series of Novel Macrocyclic Human Immunodeficiency Virus-1 Protease Inhibitors to Combat Drug ResistanceFragment-Based Screen against HIV ProteaseProbing Multidrug-Resistance and Protein-Ligand Interactions with Oxatricyclic Designed Ligands in HIV-1 Protease InhibitorsDesign of HIV-1 Protease Inhibitors with C3-Substituted Hexahydrocyclopentafuranyl Urethanes as P2-Ligands: Synthesis, Biological Evaluation, and Protein–Ligand X-ray Crystal StructureThe higher barrier of darunavir and tipranavir resistance for HIV-1 proteaseSubstituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitorsHighly Potent HIV-1 Protease Inhibitors with Novel Tricyclic P2 Ligands: Design, Synthesis, and Protein–Ligand X-ray StudiesSubstrate Envelope-Designed Potent HIV-1 Protease Inhibitors to Avoid Drug ResistanceGS-8374, a Prototype Phosphonate-Containing Inhibitor of HIV-1 Protease, Effectively Inhibits Protease Mutants with Amino Acid InsertionsCarbamylation of N-Terminal ProlineIdentification of novel HIV 1--protease inhibitors: application of ligand and structure based pharmacophore mapping and virtual screeningSynthesis and biological evaluation of new nanosized aromatic polyamides containing amido- and sulfonamidopyrimidines pendant structures.Understanding ligand-receptor non-covalent binding kinetics using molecular modeling.Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease.Co-lethality studied as an asset against viral drug escape: the HIV protease case.Computational mutation scanning and drug resistance mechanisms of HIV-1 protease inhibitorsDesign and synthesis of potent macrocyclic HIV-1 protease inhibitors involving P1-P2 ligands.Anatomy of β-strands at protein-protein interfaces.Capturing the essence of organic synthesis: from bioactive natural products to designed molecules in today's medicine.Revealing origin of decrease in potency of darunavir and amprenavir against HIV-2 relative to HIV-1 protease by molecular dynamics simulations.Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation.HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" studySolution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir.Design, synthesis and evaluation of a potent substrate analog inhibitor identified by scanning Ala/Phe mutagenesis, mimicking substrate co-evolution, against multidrug-resistant HIV-1 protease.Natural polymorphisms and unusual mutations in HIV-1 protease with potential antiretroviral resistance: a bioinformatic analysis.Synthesis and biological evaluation of novel allophenylnorstatine-based HIV-1 protease inhibitors incorporating high affinity P2-ligands.HIV-1 Protease: Structural Perspectives on Drug ResistanceMolecular Basis for Drug Resistance in HIV-1 ProteaseOrganic carbamates in drug design and medicinal chemistryDesign of gem-difluoro-bis-tetrahydrofuran as P2 ligand for HIV-1 protease inhibitors to improve brain penetration: synthesis, X-ray studies, and biological evaluation.Enantioselective Synthesis of Dioxatriquinane Structural Motifs for HIV-1 Protease Inhibitors Using a Cascade Radical CyclizationDesign of substituted bis-Tetrahydrofuran (bis-THF)-derived Potent HIV-1 Protease Inhibitors, Protein-ligand X-ray Structure, and Convenient Syntheses of bis-THF and Substituted bis-THF LigandsConserved hydrogen bonds and water molecules in MDR HIV-1 protease substrate complexes.Substituted Bis-THF Protease Inhibitors with Improved Potency against Highly Resistant Mature HIV-1 Protease PR20
P2860
Q26777448-BE9CECB2-CC7D-462E-87CF-D2E2AAD4367DQ26779035-66EF2648-8D3A-41DB-BD11-0549989A4451Q27324517-0D069F18-AE11-4CB1-B505-A1BC75BF40C0Q27652399-E9704DD3-B102-4F3A-90AA-E54A24C88786Q27654045-9B631F58-F83E-4954-A8C9-945E7DC7E06FQ27655631-559DDF66-6CFB-4569-A993-CF2CD503927DQ27657395-8155F041-3102-45EB-B260-0A10745E6179Q27663595-900D052E-30E5-4984-AAE2-5B4033719AFEQ27664394-1029185F-BA97-4E30-B747-C7FA63615B78Q27671213-C0325E0D-D17D-4F81-9E08-D47479C1D7C9Q27672193-7C917307-CEC5-4537-8A6E-7441580DE197Q27677475-C07E523F-1E7C-4050-948B-56835B167D6FQ27679692-5A6E8645-F2F8-4646-AE4F-E4481C50E49FQ27679880-222580A2-77A4-4ABB-99F7-6048C92DF804Q27681100-CA1BCCFA-9A82-45C6-A156-BBBFBF3DA5E8Q27684096-EBE984D2-0AEA-4233-B268-39415980B2E6Q28485115-37FAD59E-4FD2-423F-862A-EBF2E81DFD74Q30989375-931629DD-886A-4A36-A4A0-63E19515078AQ33796500-FFF0D281-A963-4C30-A62A-876E66EE48CEQ33870886-DD782FFC-75C6-4F09-A622-79944356C20BQ33968760-281C63C8-0F2B-4E54-A900-0613DEFFE9B2Q34044221-F526A4C2-BD9C-4CB9-A9FA-21526962DBAAQ34046931-AC50CADF-480E-4D66-B6F3-3E6087EBEC75Q34061140-CBBE03D5-7377-4D7A-9266-44BB94657C7BQ34361292-3D0C6344-6008-4F10-8F11-27F9DC865A07Q34440391-4D2B0C12-EDBB-4765-9B9C-A7E1FA8B4EE5Q34507768-95C12B46-52FD-47CA-9D33-7FF7F6926417Q34534986-51A051E8-39A1-42CF-AF43-3F4A28569F1EQ34657222-E0D6BFCD-7BAB-46EA-BB12-11C15502D958Q34885997-D3F8A6F1-545F-4D73-AB0F-BF26831D5762Q35120811-46FB3060-29E6-4278-931F-B2958A4CEAF5Q35231732-69C60307-BAC1-4425-9466-BE0AE88CB24AQ35259855-3F79F2F7-98D3-44F3-922A-313A379C201EQ35260370-91ED7DB4-42BA-4021-BC12-80BF7A970F2BQ35365543-CF8BB83E-6601-4BF8-8B56-56C870B6926CQ35569236-8E240A7B-E193-433A-A063-F2AED53128D4Q35846634-29EF734B-5EFA-4AEF-9900-87E63CB9A744Q35887425-411B658B-2290-41A6-B7E2-35CE760EFEE3Q35903710-AE0349A9-EDEF-49FB-98AE-6397A32AFF2DQ35909838-D575CA3B-72B0-4BF0-82EE-FAA9DDF4C104
P2860
Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Design of HIV protease inhibit ...... for combating drug resistance.
@en
type
label
Design of HIV protease inhibit ...... for combating drug resistance.
@en
prefLabel
Design of HIV protease inhibit ...... for combating drug resistance.
@en
P2093
P356
P1476
Design of HIV protease inhibit ...... for combating drug resistance.
@en
P2093
Arun K Ghosh
Bruno D Chapsal
Hiroaki Mitsuya
Irene T Weber
P356
10.1021/AR7001232
P407
P577
2007-08-28T00:00:00Z